Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

74 results about "Decreasing ldl" patented technology

Aerobic exercises, such as running, cycling, jogging, and swimming, appear to benefit cholesterol the most by lowering LDL and reducing the risk of cardiovascular disease, according to studies .

Cholesteryl Ester Transfer Protein Inhibitors

Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A1 is a cyclic group, and B is a cyclic group which is attached to the heterocyclic ring directly or through a methylene group.
Owner:MERCK SHARP & DOHME LLC

Methods for treating hypercholesterolemia

Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and / or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
Owner:IONIS PHARMA INC

Balanced sn-2 myristate-containing edible oil

ActiveUS8114461B2Fatty acid esterificationAnimal feeding stuffHDL/cholesterol ratioEdible oil
A nutritional fat or oil-based composition for increasing HDL cholesterol, decreasing LDL cholesterol and decreasing the LDL / HDL cholesterol ratio in human plasma is described. The composition typically includes at least 1% by weight myristic acid esterified at the sn-2 position in triglyceride molecules, includes between 10% and 40% by weight linoleic acid, and further includes between 30% and 65% by weight oleic acid and between 15% and 40% by weight total saturated fatty acids. The ratio of sn-2 myristic acid to sn-2 palmitic acid is typically greater than 1:1 and the sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free.
Owner:BRANDEIS UNIV

Composition and method of lactobacillus reuteri gmnl-89 in treating type 2 diabetes

Present invention features a novel use of Lactobacillus for treating type 2 diabetes, wherein the Lactobacillus is Lactobacillus reuteri GMNL-89 with the deposition numbers of BCRC 910340 and CCTCC M 207154 and comprises of live, dead bacteria or supernatant of the bacterial culture(s) and a pharmaceutically acceptable vehicle. The invention also discloses the efficacies of the indicated Lactobacillus strain including anti-oxidative enzyme activity, anti-inflammation, reduction of blood glucose level, reduction of triglycerides, reduction of total cholesterol, reduction of LDL, increase of HDL and improve insulin utilization.
Owner:GENMONT BIOTECH

Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses

A composition is provided which contains policosanol and niacin and / or niacin derivatives and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, Lp(a), triglycerides, coronary heart disease (heart attacks and strokes), inflammation, immunoregulatory diseases, cardiovascular diseases, deep vein thrombosis, anxiety, depression and / or neurodegenerative disorders, and / or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and niacin and / or niacin derivatives which together effectively lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to niacin and / or niacin derivatives.
Owner:WYETH LLC

Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses

InactiveUS20060020031A1Reduce and prevent hypercholesterolemic diseaseBiocideHydroxy compound active ingredientsCholesterol bloodCoronary heart disease
A composition is provided which contains policosanol and omega-3 fatty acids and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), sudden cardiac death, ventricular fibrillation, tachycardia, hypertension, inflammation, thrombosis, deep-vein thrombosis, stroke, macular degeneration, autoimmune and / or immunoregulatory diseases, cardiovascular diseases, anxiety, depression and / or neurodegenerative disorders, and / or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and omega-3 fatty acids which together effectively lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to omega-3 fatty acids.
Owner:WYETH

CETP inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
Owner:MERCK SHARP & DOHME LLC

Balanced myristate- and laurate-containing edible oil

Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL / HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and / or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and / or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol.
Owner:BRANDEIS UNIV

CETP activity inhibitors

The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I):wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X1, X2, X3, and X4 may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO2—, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.
Owner:JAPAN TOBACCO INC

CETP Inhibitors

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R2 is a phenyl group which has an ortho amine or aminomethyl substituent which is further substituted, and the other of B or R2 is also a cyclic group.
Owner:MERCK SHARP & DOHME LLC

Modification of cholesterol concentrations with citus phytochemicals

InactiveUS20020006953A1Easy to changeDecrease in LDL to HDL serum cholesterol ratioBiocideMetabolism disorderPhytochemicalSerum cholesterol level
Methods, products and compositions are provided which, when administered to a mammal, including humans, raises HDL serum cholesterol levels, while typically also lowering the ratio of LDL to HDL serum cholesterol levels. An effective amount of one or more of a monoterpene, a terpene and a flavonoid are included in the treatment composition.
Owner:TROPICANA PROD INC

Combination of medication containing reductase inhibitor HMG CoA and Melatonin

A composite medicine in the form of tablet, capsule, softgel, or dispersing tablet for preventing the atherosclerosis by cutting off the oxidization modification to low-density lipoprotein (LDL) and decreasing the LDL contains HMG-CoA reductase inhibitor (tatin-type medicine and melatonin.
Owner:LUNAN PHARMA GROUP CORPORATION

Cholesteryl ester transfer protein inhibitors

Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A1 is a cyclic group, and B is a cyclic group which is attached to the heterocyclic ring directly or through a methylene group.
Owner:MERCK SHARP & DOHME LLC

Methods of treating Syndrome X with aliphatic polyamines

The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially:where n is a positive integer and each R, independently, is H or a C1–C8 alkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.
Owner:GENZYME CORP

Balanced sn-2 myristate-containing edible oil

ActiveUS20110104326A1Raising and lowering lipoprotein levelReducing LDL-CFatty acid esterificationAnimal feeding stuffMyristic acidHDL/cholesterol ratio
A nutritional fat or oil-based composition for increasing HDL cholesterol, decreasing LDL cholesterol and decreasing the LDL / HDL cholesterol ratio in human plasma is described. The composition typically includes at least 1% by weight myristic acid esterified at the sn-2 position in triglyceride molecules, includes between 10% and 40% by weight linoleic acid, and further includes between 30% and 65% by weight oleic acid and between 15% and 40% by weight total saturated fatty acids. The ratio of sn-2 myristic acid to sn-2 palmitic acid is typically greater than 1:1 and the sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free.
Owner:BRANDEIS UNIV

Process for a CETP Inhibitor

An efficient process is disclosed for producing the compound of formula I, which is the CETP inhibitor anacetrapib, which raises HDL-cholesterol and reduces LDL-cholesterol in human patients and may be effective for treating or reducing the risk of developing atherosclerosis:
Owner:MERCK FROSST CANADA INC +1

Tea-derived compositions and methods of using same for cardiovascular health

Disclosed herein are compositions comprising tea derived components which are useful in decreasing elevated blood pressures, lowering LDL and / or lowering inflammatory markers of cardiovascular disease. Specifically exemplified herein are compositions comprising predetermined amounts of L-theanine and EGCG, and methods of using same to improve cardiovascular health.
Owner:IG IMMUNITY LLC +1

Biaryl- or Heterocyclic Biaryl-Substituted Cyclohexene Derivative Compounds as CETP Inhibitors

The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a CETP inhibitory effect that increases HDL-cholesterol levels and reduces LDL-cholesterol levels. Pharmaceutical compositions comprising the compounds are useful for the prevention or treatment of dyslipidemia or dyslipidemia-related diseases.
Owner:CHONG KUN DANG PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products